At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 38 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
Comparator: Amlodipine 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Randomized, Placebo-Controlled, 3-Period, Crossover Study to Evaluate the Effects of Antihypertensive Agents on Central Blood Pressure in Healthy Subjects and Patients With Hypertension
In Brief
A Phase 1 clinical trial evaluating Placebo, Comparator: Amlodipine, and 1 other intervention for Hypertension. Completed, enrolled 38 participants.
Detailed Summary
This study will test the relationship between CBP (central blood pressure) and PBP (peripheral blood pressure) effects after single and multiple doses of Isosorbide mononitrate extended release (ISMN ER) or Amlodipine besylate in participants with hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2010
First PostedMay 2010
Primary CompletionNov 2010
TodayJul 2026
First PostedMay 25, 2010
Enrollment StartMay 1, 2010
Primary CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 16.1 years ago
Interventions
Placebodrug
Placebo, capsule taken orally once daily during 4 weeks of treatment
Comparator: Amlodipinedrug
Amlodipine 10 mg, taken orally as two 5 mg capsules, single daily dose for 4 weeks
Comparator: ISMN ERdrug
ISMN ER 30 mg capsule, taken orally as single daily dose for 4 weeks